Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
8/15/2026
-
MarketBeat
8/14/2026
-
MarketBeat
8/14/2026
-
Tickeron - Stocks
8/14/2026
-
The Cerbat Gem
8/13/2026
-
Seeking Alpha - Healthcare
8/13/2026
-
Tickeron - Stocks
8/13/2026
-
MarketBeat
8/13/2026
-
MarketBeat
8/13/2026
-
The Cerbat Gem
8/12/2026
-
MarketBeat
8/12/2026
-
MarketBeat
8/12/2026
-
MarketBeat
8/12/2026
-
The Cerbat Gem
8/12/2026
-
MarketBeat
8/12/2026
-
MarketBeat
8/12/2026
-
TipRanks
8/12/2026
-
TipRanks
8/12/2026
-
Tickeron - Stocks
8/12/2026
-
TipRanks
8/11/2026
-
MarketBeat
8/11/2026
-
TipRanks: TheFly
8/11/2026
-
Business Wire
California State Teachers Retirement System Has $2.44 Million Stock Position in Immunome, Inc. $IMNM
8/11/2026
-
MarketBeat
8/11/2026
-
Simply Wall St
8/10/2026
-
The Cerbat Gem
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 11, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
425 939 7410
Address
18702 North Creek Parkway
Suite 100
Bothell, WA 98011
Suite 100
Bothell, WA 98011
Country
Year Founded
Business Description
Sector
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the...
more